Streetbeat News

SITC

SITE Centers Corp.

https://www.sitecenters.com

Industry

REIT - Retail

SITE Centers is an owner and manager of open-air shopping centers that provide a highly-compelling shopping experience and merchandise mix for retail partners and consumers. The Company is a self-administered and self-managed REIT operating as a fully integrated real estate company, and is publicly traded on the New York Stock Exchange under the ticker symbol SITC.

Open

13.94

Mkt cap

735M

Volume

1.2M

High

14.10

P/E Ratio

1.45

52-wk high

64.44

Low

13.80

Div yield

0.07

52-wk low

13.30

SITE Centers Corp. (SITC) released its Q4 earnings, providing insights into its performance for the quarter ending December 2024. The report includes comparisons to Wall Street estimates and previous year figures.

Portfolio Pulse from

February 27, 2025 | 4:00 pm

Xenetic Biosciences, Inc. announced that its abstract on enhancing CAR-T cell therapy in solid tumors has been accepted for a poster presentation at the SITC Spring Scientific 2025 Cell Therapy Meeting.

Portfolio Pulse from

February 27, 2025 | 2:30 pm

SITE CENTERS CORP. (SITC) reported Q4 funds from operations (FFO) of $0.16 per share, missing the Zacks Consensus Estimate of $0.23 per share.

Portfolio Pulse from

February 27, 2025 | 2:00 pm

HOOKIPA Pharma's eseba-vec, in combination with pembrolizumab, showed promising results in a Phase 2 trial, achieving a 52% overall response rate in patients with PD-L1 CPS>20. The trial also reported encouraging progression-free survival and overall survival data, with a strong T cell response and good safety profile.

Portfolio Pulse from

November 11, 2024 | 9:30 pm

Immatics is set to present multiple clinical and preclinical-stage candidates at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), showcasing their TCR-T PRAME franchise aimed at targeting solid cancers.

Portfolio Pulse from

November 08, 2024 | 10:15 pm

Anixa Biosciences presented positive data from its Phase 1 study of a breast cancer vaccine at the SITC Annual Meeting. The vaccine was safe, well-tolerated, and showed immune responses in over 70% of patients. A Phase 2 study is planned for 2025.

Portfolio Pulse from

November 08, 2024 | 6:30 pm

Compass Therapeutics presented new biomarker data related to its CTX-471 clinical activity at the SITC Annual Meeting. This data is part of a Phase 1 trial for CTX-471, an anti-CD137 agonist antibody.

Portfolio Pulse from

November 08, 2024 | 3:15 pm

Medicenna presented preclinical data on its innovative cancer therapies, including the anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist programs, at the SITC annual meeting. These therapies are designed to target tumors more effectively by activating in the tumor microenvironment.

Portfolio Pulse from

November 08, 2024 | 3:15 pm

BriaCell Therapeutics Corp. presented promising preclinical data on its personalized off-the-shelf immunotherapies for breast and prostate cancer at the 2024 SITC Conference. The data showcased strong anti-cancer activity of Bria-BRES+™ and Bria-PROS+™.

Portfolio Pulse from

November 08, 2024 | 1:00 pm

Innate Pharma SA announced that it will present new preclinical data on its next-generation antibody-drug conjugate and tetra-specific ANKET® at the SITC Annual Meeting 2024. This highlights the potential of their innovative oncology portfolio.

Portfolio Pulse from

November 08, 2024 | 6:15 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.